What is Aditxt Profitability Rank?
Aditxt has the Profitability Rank of 0.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Aditxt's Operating Margin % for the quarter that ended in Mar. 2024 was -14,420.00%. As of today, Aditxt's Piotroski F-Score is 2.
Competitive Comparison of Aditxt's Profitability Rank
For the Biotechnology subindustry, Aditxt's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aditxt's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aditxt's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Aditxt's Profitability Rank falls into.
Aditxt Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Aditxt has the Profitability Rank of 0.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Aditxt's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Aditxt has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Aditxt (Aditxt) Business Description
Traded in Other Exchanges
N/A
Address
737 North Fifth Street, Suite 200, Richmond, VA, USA, 23219
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes a tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.
Executives
| Charles Athle Nelson |
director |
11-F, BUILDING 12, SUNKING PLAZA, GAOJIAO ROAD, HANGZHOU, ZHEJIANG F4 311122 |
| Bnp Paribas Securities Corp |
10 percent owner |
787 SEVENTH AVE, NEW YORK NY 10019 |
| Matthew Shatzkes |
officer: Chief Legal Officer and GC |
737 N. FIFTH STREET, SUITE 200, RICHMOND VA 23219 |
| Lauren Chung |
director |
1620 BEACON STREET, OXNARD CA 93033 |
| Thomas J Farley |
officer: PRINCIPAL ACCOUNTING OFFICER |
2569 WYANDOTTE ST., SUITE 101, MOUNTAIN VIEW CA 94043 |
| Jeffrey W. Runge |
director |
C/O PHARMATHENE, INC., ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401 |
| Rowena Albanna |
officer: CHIEF OPERATING OFFICER |
11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354 |
| Rosland Fisher Mcleod |
director |
11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354 |
| Pankovcin Corinne |
officer: CHIEF FINANCIAL OFFICER |
BUSINESS DEVELOPMENT CORP OF AMERICA, 405 PARK AVENUE, 14TH FLOOR, NEW YORK NY 10022 |
| Laura E Anthony |
director |
LAURA ANTHONY, 120 S. OLIVE AVE, WEST PALM BEACH FL 33401 |
| Namvar Kiaie |
director |
11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354 |
| Brian Michael Brady |
director |
11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354 |
| Amro A. Albanna |
director, officer: CHIEF EXECUTIVE OFFICER |
871 MARLBOROUGH AVENUE, SUITE 100, RIVERSIDE CA 92507 |
| Shahrokh Shabahang |
director, officer: CHIEF INNOVATION OFFICER |
11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADTX has been successfully added to your